Loading clinical trials...
Loading clinical trials...
A Phase 2/3, Multicenter, Open-Label Phase Followed by a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children With Hypochondroplasia: ACCEL 2/3
Conditions
Interventions
infigratinib 0.128 mg/kg/day
infigratinib 0.25 mg/kg/day
Locations
22
United States
UCSF Benioff Children's Hospital
Oakland, California, United States
Childrens Hospital Colorado
Aurora, Colorado, United States
Children's National Hospital
Washington D.C., District of Columbia, United States
Johns Hopkins School of Medicine
Baltimore, Maryland, United States
University of Missouri
Columbia, Missouri, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Start Date
April 22, 2025
Primary Completion Date
January 1, 2027
Completion Date
January 1, 2027
Last Updated
December 15, 2025
NCT07126262
NCT06212947
NCT06455059
Lead Sponsor
QED Therapeutics, a BridgeBio company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions